All In Biotech

Drug Trial Radar · NCT06952517

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Efficacy and Safety of Topical Clascoterone Cream 1% in Patients With Facial Acneiform Rosacea

Last checked: Nov 20, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Sep 1, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Narrows Institute for Biomedical ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sun Pharmaceutical Industries Limited
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Conditions

  • Papular-pustular Rosacea
  • Papulopustular Rosacea (PPR)
  • Papulopustular Rosacea

Interventions

  • Clascoterone Cream 1%Drug

    Clascoterone 1% cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biopsy proven reduction in size of sebaceous glands at the end of 12 weeks of treatment compared to the baseline.Time frame: From enrollment to end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York Harbor VA Brooklyn Campus

    Brooklyn, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.